← Back to Search

Insulin

AT247 for Type 1 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Arecor Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-60 minutes
Awards & highlights

Study Summary

Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants with type 1 diabetes mellitus (T1DM) during continuous subcutaneous infusion (CSII)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-60 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-60 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under Curve for Glucose Infusion Rate
Area under Curve for serum insulin

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: AT247Experimental Treatment3 Interventions
0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
Group II: Fiasp®Active Control3 Interventions
0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
Group III: NovoLog®Active Control3 Interventions
0.02 U/Kg/H Basal via continuous subcutaneous infusion with 2 bolus 0.15 U/Kg doses in a glucose clamp for one 3-day period
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fiasp
2019
Completed Phase 4
~150
NovoLog
2022
Completed Phase 3
~250
AT247
2019
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Arecor LimitedLead Sponsor
3 Previous Clinical Trials
97 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
2022. "AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05184868.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top